| scholarly article | Q13442814 |
| P2093 | author name string | Trevor Thompson | |
| Timothy Styles | |||
| Vivien W Chen | |||
| Xiao-Cheng Wu | |||
| Cyllene R Morris | |||
| Mei-Chin Hsieh | |||
| Mary B O'Flarity | |||
| P2860 | cites work | Enhancing cancer registry data for comparative effectiveness research (CER) project: overview and methodology. | Q30871265 |
| Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data | Q31011382 | ||
| Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer | Q33372496 | ||
| The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study | Q33432354 | ||
| Comorbidities, functional limitations, and geriatric syndromes in relation to treatment and survival patterns among elders with colorectal cancer | Q33997290 | ||
| CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. | Q34084652 | ||
| Reasons physicians do not recommend and patients refuse adjuvant chemotherapy for stage III colon cancer: a population based chart review | Q34296147 | ||
| Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases | Q34439990 | ||
| Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? | Q34546887 | ||
| The impact of low-grade toxicity in older people with cancer undergoing chemotherapy | Q34686967 | ||
| Irinotecan in the treatment of colorectal cancer | Q36588563 | ||
| Refining the chemotherapy approach for older patients with colon cancer | Q38234855 | ||
| History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis | Q40204149 | ||
| Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. | Q40410722 | ||
| First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin | Q40580831 | ||
| Cancer burden in the aged: an epidemiologic and demographic overview | Q40881281 | ||
| Impact of race/ethnicity and socioeconomic status on adjuvant chemotherapy use among elderly patients with stage III colon cancer | Q43411655 | ||
| Age and adjuvant chemotherapy use after surgery for stage III colon cancer | Q43534600 | ||
| A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients | Q43763447 | ||
| Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer | Q43902636 | ||
| Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer | Q44155885 | ||
| Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer | Q44217665 | ||
| Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? | Q44229372 | ||
| Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. | Q44919656 | ||
| Evaluation of Charlson-Age Comorbidity Index as predictor of morbidity and mortality in patients with colorectal carcinoma | Q45215973 | ||
| The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening | Q51777644 | ||
| Impact of Patient Age and Comorbidity on Surgeon Versus Oncologist Preferences for Adjuvant Chemotherapy for Stage III Colon Cancer | Q58819363 | ||
| NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer | Q68536918 | ||
| Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report | Q72525174 | ||
| Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base | Q73446824 | ||
| Personalizing cancer care: American Society of Clinical Oncology presidential address 2009 | Q84184601 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colon cancer | Q18555025 |
| comorbidity | Q1414874 | ||
| P1104 | number of pages | 10 | |
| P304 | page(s) | 871-880 | |
| P577 | publication date | 2016-01-15 | |
| P1433 | published in | Cancer Medicine | Q27724564 |
| P1476 | title | The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients | |
| P478 | volume | 5 |
| Q59138464 | Age-adjusted charlson comorbidity index and 30-day morbidity in pelvic surgeries |
| Q47126640 | Electrochemical and optical biosensors for early-stage cancer diagnosis by using graphene and graphene oxide. |
| Q90251779 | Impact of adjuvant chemotherapy on the survival of patients with breast cancer diagnosed by screening |
| Q88188562 | Preliminary clinical application of an aromatase inhibitor and a gonadotropin-releasing hormone agonist combination for inoperable endometrial cancer patients with comorbidities: case report and literature review |
| Q90387009 | The Association between Chronic Conditions, End-of-Life Health Care Use, and Documentation of Advance Care Planning among Patients with Cancer |
| Q33739235 | The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy |
| Q90354197 | Treatment selection bias for chemotherapy persists in colorectal cancer patient cohort studies even in comprehensive propensity score analyses |
Search more.